Physician profile
Michael Heinle
NPI 1154343556
$9,292.01
in general payments reported to CMS, 2019-2025
39 companies · $1,697 in 2025
The $1,697 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,819 · 2020: $523 · 2021: $1,234 · 2022: $1,234 · 2023: $1,416 · 2024: $1,369 · 2025: $1,697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,450 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,450.13 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,816.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,517.94 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,071.37 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $788.66 | 2019-2025 | Repatha, Evenity, Prolia |
| Phathom Pharmaceuticals, INC. | $435.63 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $393.25 | 2019-2024 | Mounjaro, Zepbound |
| Pfizer INC. | $377.82 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $336.73 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $291.62 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.10 | 2019-2025 | Jardiance, Stiolto Respimat, Tradjenta |
| Sanofi-Aventis U.S. LLC | $243.79 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $155.10 | 2019-2025 | Breztri |
| Otsuka America Pharmaceutical, INC. | $153.16 | 2022-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $128.17 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Edwards Lifesciences Corporation | $127.75 | 2023-2024 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Heinle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.